Clinical trial
A Phase I, First-in-human, Two-part, Randomized, Placebo-controlled, Double-blind, Single and Repeated Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Doses of SAR442501 in Healthy Adult Subjects
NCT05846009 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I, First-in-human, Two-part, Randomized, Placebo-controlled, Double-blind, Single and Repeated Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Doses of SAR442501 in Healthy Adult Subjects
- Lead sponsor
- Sanofi
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- November 18, 2020
- Completion date
- January 12, 2022
- Enrollment
- 76 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
osteochondrodysplasia